Abstract 1044P
Background
For product development, GMP production, quality control for product release and immune monitoring of patient samples, three methods are typically used to identify rTCR expression in TCR-T populations: (1) detection of an extra tag that is co-expressed with the rTCR; (2) binding of antibodies specific for TCR Vß-chains, or (3) rTCR binding of peptide-HLA multimers. The latter two approaches must be tailored for each rTCR and high-quality reagents may not be readily available.
Methods
Using bioinformatics and 3D modeling of TCRs, novel synthetic epitopes were designed and inserted at different positions in multiple rTCR sequences. Internally tagged rTCRs were assessed for surface expression, functionality and target specificity, as well as for binding of an antibody (TraCR) detecting the synthetic epitopes of different length.
Results
Identifying a unique, synthetic epitope (UniTope) and optimal insertion sites localized in the rTCR constant regions permitted highly specific detection by the TraCR antibody. The UniTope & TraCR combination unambiguously distinguishes rTCRs expressed in recipient T cells from all endogenous TCRs found in PBL. The integrated UniTope tag exclusively binds TraCR antibody, and not alter functionality, established safety profiles or expression levels of any of the assessed rTCRs.
Conclusions
UniTope & TraCR is a universal detection system for rTCRs easy to adapt for multi-parameter flow cytometry. Seamless integration of UniTope in any rTCR structure bypasses need for co-expression of a separate gene sequence to universally tag rTCR-expressing T cells. Providing a standardized detection system, UniTope & TraCR simplifies supply and validation of quality control assays for TCR-T therapies covering all rTCRs, providing precise information for drug product dosing. It allows easy visualization, isolation and enrichment of TCR-T cells for direct study. GMP-grade TraCR can be applied for drug product enrichment and potentially also to trace TCR-T cell localization and persistence in vivo, supporting immune monitoring in patients. The UniTope & TraCR system is a high precision technology that facilitates optimized development of TCR-T therapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1014P - Phase Ib trial results of safety, pharmacokinetics and pharmacodynamics of TU2218, TGFβ-RI and VEGF-R2 dual inhibitor in combination with pembrolizumab in patients with advanced solid tumors
Presenter: Anthony Tolcher
Session: Poster session 03
1015P - The efficacy and mechanism of pan-FGFR inhibitor (AZD4547) combined with immunoagonists or immunosuppressants in FGFR-positive tumors
Presenter: Qizhi Ma
Session: Poster session 03
1016P - Phase I study of SOF10 plus atezolizumab in patients with advanced/recurrent solid tumours
Presenter: Toshihiko Doi
Session: Poster session 03
1017P - Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)
Presenter: Samuel Klempner
Session: Poster session 03
1018P - Leveraging innate and adaptive immunity with AFM24 and atezolizumab in metastatic gastric cancer
Presenter: Omar Saavedra Santa Gadea
Session: Poster session 03
1019P - Bispecific PD1-IL2 antibody reshapes the inhibitory immune microenvironment of SMARCA4 mutant non-small cell lung cancer by reversing CD8+T cell exhaustion
Presenter: Bo Cheng
Session: Poster session 03
Resources:
Abstract
1020P - Highly potent and specific bivalent T cell engager (TCE) targeting PRAME on HLA-A*02:01
Presenter: Athanasia Dasargyri
Session: Poster session 03
1021P - Chemotherapy and hypomethylating agents enhance anti-tumor activity of PRAME ImmTAC
Presenter: Adel Benlahrech
Session: Poster session 03
1022P - A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: Completed cohort for first-line (1L) treatment of advanced squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Jonathan Riess
Session: Poster session 03
1023P - Long-term follow up of patients treated with a DNA vaccine (pTVG-HP) for PSA-recurrent prostate cancer
Presenter: Douglas McNeel
Session: Poster session 03